WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Abrir esta carpeta y ver su contenidoInsect and arachnid bites and stings
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Abrir esta carpeta y ver su contenidoViral infections
Abrir esta carpeta y ver su contenidoEczematous diseases
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Abrir esta carpeta y ver su contenidoPremalignant lesions and malignant tumours
Cerrar esta carpetaPhotodermatoses
Ver el documentoSolar urticaria
Ver el documentoPolymorphous light eruptions
Ver el documentoActinic prurigo
Ver el documentoChemical photodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Abrir esta carpeta y ver su contenidoAnti-inflammatory and antipruritic drugs1
Abrir esta carpeta y ver su contenidoAntiallergics and drugs used in anaphylaxis
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Actinic prurigo

Actinic prurigo, which occurs particularly among people of American Indian and Asian descent, first appears during childhood. It usually regresses completely during adolescence and early adulthood but can persist longer. Recurrent patchy oedematous erythema results in the formation of persistent excoriated plaques, papules and nodules. Cheilitis is common, particularly during the early phases of the disease. Vesicles and small pitted scars sometimes develop on the face, while chronic conjunctivitis and pterygium formation are common among affected children in South America, New Mexico and Saskatchewan, Canada.

Treatment

Sunscreens, when used regularly, provide some protection. The cutaneous signs are suppressed by thalidomide and, to a lesser extent, topical corticosteroids, but they recur within a few weeks of discontinuation of treatment. Thalidomide should be avoided in women of child-bearing age, since it is a proven teratogen. If this is not possible, it is imperative that pregnancy be excluded before this treatment is instituted. Effective contraception must be used during the 4 weeks preceding and following treatment, as well as during the treatment period. Should pregnancy occur despite these precautions, there is a high risk of severe malformation of the fetus.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019